Abstract Background Durable treatment effectiveness is an important consideration in the long-term management of patients with Crohn’s disease (CD) receiving biologic therapy. The aim this analysis was to evaluate rates failure and dose modification for over time CD using data from a large observational study evaluating secondary outcomes initiating on vedolizumab (VDZ) other biologics. Methods...

INTRODUCTION The long-term course of rheumatoid arthritis (RA) in terms of health status is not well understood, nor is the degree of effectiveness of biologic therapy in the community. We modeled the progression of loss of health status, and measured incremental costs and effectiveness of biologic therapy in the community. METHODS We studied change in function and health status in 18,485 RA ...

Clinical evidence demonstrates coadministration of tumour necrosis factor inhibitor (TNFi) agents and methotrexate (MTX) is more efficacious than administration of TNFi agents alone in patients with rheumatoid arthritis, leading to the perception that coadministration of MTX with all biologic agents or oral disease-modifying antirheumatic drugs is necessary for maximum efficacy. Real-life regis...

The medical treatment of metastatic colorectal cancer (mCRC) has advanced significantly over the last 10 years as the result of the introduction of several active cytotoxic and biologic agents into standard clinical practice. Several recent phase III trials reported median overall survival data exceeding 30 months, an achievement inconceivable only 5 years ago.The first major step forward in th...

Over the past decade, the treatment of rheumatoid arthritis has been revolutionised by the development of therapies targeted at molecules involved in driving the inflammatory response. This review briefly summarises the established uses of biologic therapies in rheumatoid disease, and outlines other diseases in rheumatology and other fields where biologic agents are finding a role.

Systemic lupus erythematosus (SLE), the prototype of systemic autoimmune diseases is characterized by extreme heterogeneity with a variable clinical course. Renal involvement may be observed and affects outcome. Hydroxychloroquine should administered to every patient irrespective organ involvement. Conventional immunosuppressive therapy includes corticosteroids, methotrexate, cyclophosphamide, ...

Significant data on applied biologic drugs can be found in national registries of treated patients. The main reason of establishing registries is monitoring the efficacy and safety of biologic drugs in long-term treatment. Registries provide information on outcome of the disease, life quality, and risk-benefit ratio including society costs.

Over the past decade, biologic therapies have been developed to treat auto-inflammatory conditions such as psoriasis. They have the advantage of better target specificity than traditional systemics such as methotrexate and cyclosporine and therefore significantly reduce side-effects and toxicity associated with wide spread systemic treatments. It has been suggested that the efficacy of biologic...